Aim: To evaluate role of Mifepristone and Ulipristal acetate in the treatment of symptomatic uterine fibroids.

Methods: The present randomized comparative prospective study was conducted among non-pregnant and non-lactating females of age 25-50 years with symptomatic fibroids reported in the Department of Obstetrics & Gynaecology.The selected subjects were divided into two treatment arms i.e. GROUP 1): Ulipristal Acetate: 5mg OD for 3 months and GROUP 2): Mifepristone: 25mg OD for 3 months. A Blood examination, USG (pelvis), PAP, Smear and Endometrial Biopsy was done. Subjects visited the hospital at visit 1, visit 2, visit 3, visit 4, visit 5 and visit 6 for 6 months.

Results: When mean PBAC score at first, second, third, fourth and fifth visit was compared statistically among Ulipristal acetate and Mifepristone group, it was found to be statistically significant. Size was reduced more in Mifepristone group as compared to Ulipristal acetate group at all the different intervals.

Conclusions: We concluded from this study that Mifepristone should be preferred over Ulipristal acetate for treatment of symptomatic fibroids